Safety
fatty liver, hypertension
FATTY LIVER, CNS INFECTIONS, RETINAL DETACHMENT, HYPERTENSION, TYPE 2 DIABETES MELLITUS, CORONARY ARTERY DISEASE
AEs that occur up to 28 days post-vaccination, based on reported data, are all mild. Non-COVID AE for up to 28 days was reported by 64.5% of phase I subjects and 53.6% of phase II subjects, and there were no significant differences between treatment groups (The short-term AE incidence rate of DC vaccines is lower compared to conventional COVID-19 vaccines (AE Non-COVID up to 1 year COVID-19 vaccine clinical trial.NA, Data not available.* Reported data are AE phase III clinical trials in the treatment group.The meaning of bold values are the result from our study. There was an incidence of type 2 diabetes mellitus, hypertension, coronary artery disease, fatty liver, retinal detachment, and other infections in phase II subjects (